Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality.
Thessa LaeremansSabine den RooverCynthia LunguSigrid D'haeseRob A GrutersSabine D AllardJoeri L AertsPublished in: NPJ vaccines (2023)
Although natural killer (NK) cells have been studied in connection with dendritic cell (DC)-based vaccination in the field of cancer immunology, their role has barely been addressed in the context of therapeutic vaccination against HIV-1. In this study, we evaluated whether a therapeutic DC-based vaccine consisting of monocyte-derived DCs electroporated with Tat, Rev and Nef encoding mRNA affects NK cell frequency, phenotype and functionality in HIV-1-infected individuals. Although the frequency of total NK cells did not change, we observed a significant increase in cytotoxic NK cells following immunisation. In addition, significant changes in the NK cell phenotype associated with migration and exhaustion were observed together with increased NK cell-mediated killing and (poly)functionality. Our results show that DC-based vaccination has profound effects on NK cells, which highlights the importance of evaluating NK cells in future clinical trials looking at DC-based immunotherapy in the context of HIV-1 infection.
Keyphrases
- nk cells
- dendritic cells
- hiv infected
- antiretroviral therapy
- human immunodeficiency virus
- hiv positive
- regulatory t cells
- immune response
- clinical trial
- hiv aids
- hepatitis c virus
- cell therapy
- hiv testing
- single cell
- randomized controlled trial
- papillary thyroid
- mesenchymal stem cells
- bone marrow
- double blind
- squamous cell carcinoma
- intellectual disability
- phase ii
- lymph node metastasis